Faricimab can reduce vascular leakage and inflammation in patients who demonstrated a poor response to other anti-VEGF agents.

Faricimab is a bispecific antibody that targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) – that drive a number of retinal conditions ...

Hoffmann-La Roche, and Teva. Clinic capacity constraints are an ever-increasing problem in ophthalmology. Multiple case studies demonstrate that faricimab frees up clinic capacity with extended ...

Roche said that faricimab is the "first and only" FDA-approved injectable for both wet AMD and DME that is every four to 16 weeks, while Eylea (aflibercept) needs to be administered every eight or ...

SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.

其中罗氏的用于治疗血友病的Hemlibra全球销量最高，2024年销售额达到45.03亿瑞士法郎（约53.61亿美元）。其次是罗氏的眼科药物Vabysmo增长迅速，2024年销售额为38.64亿瑞士法郎（约46.0亿美元），加上Columvi和Lunsumio，罗氏双抗规模已超百亿美元，占有绝对领先地位（图1）。

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.